Deal adds drug analysis to Millipore offerings

Millipore is establishing a beachhead extending its reach into Europe, the home turf of competitor Sartorius Stedim Biotech, through the acquisition of U.K.-based BioAnaLab, a specialist service provider for biologic drug and vaccine analysis.

The deal lets Millipore further establish its biopharmaceutical services business and fortify its status as an outsource partner, according to a company announcement. BioAnaLab brings GMP support testing capabilities and its customer base to the deal. The Oxford company was spun out of the University of Oxford in 2002.

For its part, Goettingen, Germany-based Sartorius Stedim announced in July that it is partnering with cell culture media specialist SAFC Biosciences to provide fluid management and liquid/powder system solutions for upstream and downstream processing. The deal is expected to further the German company's offerings of single-use bioprocess technology.

- see the Millipore announcement
- here's the Sartorius Stedim release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.